| The role of parity in medical abortion up to 49 days of amenorrhoea. | |
| | |
MedLine Citation:
|
PMID: 19117257 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To identify possible risk factors for failure of medical abortion. METHOD: Retrospective study of data collected between 1 January 2001 and 31 December 2005, concerning 1850 women who, for medical abortion up to 49 days of amenorrhoea, had received 600 mg oral mifepristone followed 48 h later by 400 microg oral misoprostol and, if necessary, a second oral dose of 400 microg. RESULTS: The method was effective in 97.1% of cases. Fifty four failures (2.9%) were recorded, including seven continuing pregnancies (0.4%). The global efficacy rate of this mifepristone-misoprostol regimen is among the best using similar treatment protocols. The proportion of failures augmented with parity. CONCLUSION: This study suggests that parity is a major factor influencing the success of medical abortion. A greater parity of the patients was associated with a lower efficacy of treatment. |
| | |
Authors:
|
Philippe Lefebvre; Martine Cotte; Nicole Monniez; Gerard Norel |
Related Documents
:
|
21747817 - Gas discharge visualization: an imaging and modeling tool for medical biometrics. 1747807 - Postpartum hemorrhage. 3577197 - The medical treatment of battered wives. 20347397 - Issues in second trimester induced abortion (medical/surgical methods). 12430947 - Flag errors in soccer games: the flash-lag effect brought to real life. 10219387 - Suppression of post-caloric nystagmus in experimental perilymph fistula. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception Volume: 13 ISSN: 1473-0782 ISO Abbreviation: Eur J Contracept Reprod Health Care Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2009-01-01 Completed Date: 2009-04-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9712127 Medline TA: Eur J Contracept Reprod Health Care Country: England |
Other Details:
|
Languages: eng Pagination: 404-11 Citation Subset: IM |
Affiliation:
|
Service d'Orthogenie, Centre Hospitalier de Roubaix, Roubaix, France. philippe.lefebvre@ch-roubaix.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abortifacient Agents, Steroidal
/
administration & dosage,
adverse effects Abortion, Induced / adverse effects* Adolescent Adult Amenorrhea / etiology* Chorionic Gonadotropin / blood Cohort Studies Dose-Response Relationship, Drug Female Humans Middle Aged Mifepristone / administration & dosage, adverse effects Misoprostol / administration & dosage, adverse effects Parity* Pregnancy ROC Curve Retrospective Studies Risk Factors Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Abortifacient Agents, Steroidal; 0/Chorionic Gonadotropin; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Male partner involvement and assistance in female condom use.
Next Document: Determinants of choosing withdrawal over modern contraceptive methods in Turkey.